# A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

> **NCT06046729** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 352 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Eltrekibart
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06046729
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-23
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-08
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046729, "A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06046729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*